Nuance Biotech

Emergency Care

The page describes iron deficiency anemia.

Nuance Pharma are an innovation focused biopharmaceutical company, with both late-stage clinical pipeline and commercial stage asset portfolio across respiratory, emergency care, iron deficiency anemia and pain management.

Nuance Pharma begins dosing the first patient in its **REACH Phase III trial** of **STG320 (Actair®)**, a treatment for **house dust mite-induced allergic rhinitis**, in China. The trial marks a key milestone for the biopharmaceutical company’s development of the therapy. STG320 targets allergic rhinitis, a condition affecting millions globally. Nuance Pharma’s Phase III study aims to further validate the drug’s safety and efficacy in a broader patient population.

Oct 2026PR NewswireNews article

Nuance Pharma secures **IND clearance** from China’s NMPA for its **Actair®** pivotal clinical trial, advancing house dust mite allergy immunotherapy for Chinese patients. The approval marks a critical milestone in the drug’s regulatory pathway, enabling patient enrollment in China. Actair® targets a common respiratory allergy affecting millions globally.

May 2026PR NewswireNews article

Nuance Pharma publishes Phase 3 trial results showing Ohtuvayre® (ensifentrine) improves lung function in Chinese adult patients. The data appears in the peer-reviewed *CHEST* journal, validating the drug’s efficacy in a clinical setting. The study, named ENHANCE-CHINA, contributes to the growing body of evidence for ensifentrine’s respiratory benefits.

Apr 2026PR NewswireNews article

Nuance Pharma secures regulatory approval for **Ohtuvayre® (ensifentrine)**, a COPD treatment, in **Hong Kong SAR, China**. This marks its second approval outside the U.S., expanding patient access in select **Special Administrative Regions (SARs)** of Greater China. The drug targets chronic obstructive pulmonary disease (COPD) and follows prior U.S. FDA clearance.

Mar 2026PR NewswireNews article